Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|December 19, 2013
An Analysis of the DECISION Trial
Author(s)Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose, MD, PhD, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.
Advertisement
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.
Clinical Pearls:
- The DECISION trial was a placebo-controlled, randomized trial that tested the efficacy of sorafenib in patients with differentiated thyroid cancer that had progressed following radioactive iodine
- These patients were randomized 1:1 to either sorafenib or placebo
- The results showed that the progression-free survival in the sorafenib arm was significantly increased to 10.8 months compared to 5.8 months in the placebo arm
- This data is statistically significant with a hazard ratio of .587 and aPvalue of less than .0001
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Elinzanetant Gets Priority Review for VMS From Breast Cancer Endocrine Therapy
5